Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1996 1
1997 1
2008 1
2009 1
2010 1
2011 4
2012 6
2013 2
2014 2
2015 3
2016 3
2017 4
2018 5
2019 4
2020 2
2022 7
2023 10
2024 5
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, Belzberg AJ, Bornhorst M, Bredella MA, Cai W, Ferner RE, Gross AM, Harris GJ, Listernick R, Ly I, Martin S, Mautner VF, Salamon JM, Salerno KE, Spinner RJ, Staedtke V, Ullrich NJ, Upadhyaya M, Wolters PL, Yohay K, Widemann BC. Fisher MJ, et al. Among authors: ly i. Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146. Neuro Oncol. 2022. PMID: 35657359 Free PMC article. Review.
Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1.
Lucas CG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M, Pekmezci M, Quezado M, Rodriguez FJ, Stemmer-Rachamimov A, Viskochil D, Perry A; Symposium on Atypical Neurofibroma: State of the Science Members. Lucas CG, et al. Neuro Oncol. 2025 Mar 7;27(3):616-624. doi: 10.1093/neuonc/noae235. Neuro Oncol. 2025. PMID: 39500722 Free PMC article.
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J. Karschnia P, et al. Among authors: ly i. Neuro Oncol. 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118. Neuro Oncol. 2023. PMID: 37402650 Free PMC article.
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
Nakhate V, Ly I, Muzikansky A, Rapalino O, Allen JC, Blakeley JO, Campian JL, Clapp DW, Dhall G, Jain RK, Karajannis MA, Packer RJ, Tonsgard J, Ullrich NJ, Korf BR, Fisher MJ, Plotkin SR; Neurofibromatosis Clinical Trials Consortium. Nakhate V, et al. Among authors: ly i. J Neurooncol. 2025 Jul;173(3):751-757. doi: 10.1007/s11060-025-05020-1. Epub 2025 May 28. J Neurooncol. 2025. PMID: 40434540 Clinical Trial.
61 results